ArticleVascular health and risk management2025
Association Between Sarcopenia Index and Incident Cardiovascular Events in a Chinese Aging Population: Prospective Analysis of the CHARLS Study.
Article in Vascular health and risk management, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Sarcopenia as a Prognostic Marker of Early Mortality After Surgery for Acute Aortic Dissection: A Prospective Cohort Study.Medical sciences (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The Sarcopenia Index (SI), derived from the serum creatinine to cystatin C ratio, is a potential biomarker for cardiovascular disease (CVD). However, its prognostic significance for incident CVD in aging Chinese populations remains insufficiently characterized, despite established links between sarcopenia and CVD progression. Patients and Methods: This prospective cohort study utilized data from the China Health and Retirement Longitudinal Study (CHARLS). A total of 4979 participants aged > 45 years without prevalent CVD at baseline were included (mean age 58.0 years). Participants were categorized into Sarcopenia Index (SI) tertiles as follows: Q1 (SI ≤ 71.10), Q2 (71.10 < SI ≤ 84.75), and Q3 (SI > 84.75). Incident CVD events were assessed over a 9-year follow-up period. Multivariable Cox proportional hazards models, adjusted for demographic factors, comorbidities, and lipid profiles, were employed to evaluate associations. Restricted cubic spline (RCS) analysis was used to evaluate the dose-response relationship between SI and CVD risk. Results: In the total population, the cumulative incidence of CVD was 23.5%. The lowest SI tertile (Q1) exhibited the highest cumulative CVD incidence (27.0%), compared to Q2 (23.2%) and Q3 (20.4%). After multivariable adjustment, individuals in Q1 showed a significantly increased risk of CVD compared to those in Q3 (HR: 1.249, 95% CI: 1.054, 1.478, Conclusion: Reduced SI independently predicts elevated CVD risk in aging adults, underscoring its potential as an accessible, cost-effective screening biomarker. Integration of SI into routine clinical assessments may enhance early risk stratification and guide targeted preventive strategies, particularly for high-risk subgroups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.